Guideline Management of Chronic Heart Failure
|
|
- James Melton
- 6 years ago
- Views:
Transcription
1 Guideline Management of Chronic Heart Failure 2013 ACC/AHA Guideline Mgmt HF 2016 ACC/AHA/HFSA Focused Update 2017 ACCAHA/HFSA Focused Update October 17 th, 2017 Dawn Lombardo DO, MSc Professor of Medicine/Clinical HS University of California, Irvine Medical Center Division of Cardiology/DOM Medical Director Advanced Heart Failure Program Program Director Cardiovascular Fellowship Program
2 Disclosures None 2
3 Learning Objectives: 1. Describe the evaluation of patients presenting with stable heart failure 2. Use recent guidelines to select appropriate medical therapies for patients with stable heart failure with reduced EF 3. Develop appropriate management strategies for the patient with stable heart failure with preserved EF 3
4 Key References ACCF / AHA Heart Failure Guidelines ACCF/ AHA heart Failure Guidelines Update full.pdf HFSA Guidelines 4 October
5 Definition of Heart Failure HFSA 2010 Practice Guideline Syndrome caused by cardiac dysfunction Neurohormonal & circulatory abnormalities Characteristic symptoms: Fluid retention Shortness of breath Fatigue, especially on exertion Physiologic description: Elevated cardiac filling pressures OR Inadequate peripheral oxygen delivery at rest or during stress caused by cardiac dysfunction 5
6 Definition of Heart Failure HFSA 2010 Practice Guideline HF is progressive and often fatal ****Patients can be stabilized! **** Myocardial dysfunction and remodeling may improve Spontaneously Consequence of therapy 6
7 Definition of Heart Failure ACC/AHA 2013 Guidelines 7
8 Heart Failure in the US A Growing Problem 6.6 million Americans with HF projected ~ 8 million by ,000 new HF diagnoses annually 300, ,000 Americans with advanced HF 1 million hospitalizations /year Deaths > 300,000 HF/year mortality remain ~ 50% at 5 years. $32 billion/year expected to rise to $70 billion by % due to hospitalizations.
9 Burden of Heart Failure
10 Stages of Heart Failure 10
11 NYHA-FC and Mortality 11
12 Stages, Phenotypes and Treatment of Heart Failure 12
13 Residual Risk for HFrEF Despite Conventional GDMT 13
14 Heart Failure w/preserved Ejection Fraction vs Reduced Ejection Fraction HFpEF & HFrEF: A clinical syndrome characterized by breathlessness, fatigue and edema caused by an abnormality of the heart. E. Braunwald modified by B. Borlaug and M Redfield HFrEF & HFpEF Similar Signs and Symptoms HFpEF & HFrEF: Poor quality of life Premature mortality High hospitalization rates Substantial health-care resource utilization HFpEF = EF >= 50% + S/S + DD HFpEF DD DD = part of normal human aging & seen in many people who never have HFpEF DD = RF for HFpEF Edelmann, et al. 2011; Hamo, et al. 2015; Redfield MM, et al. 2017
15 Risk Scoring I IIa IIb III Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with HF.
16 Risk Scores to Predict Outcomes in HF Risk Score Reference (from full-text guideline)/link Chronic HF All patients with chronic HF Seattle Heart Failure Model (204) / Heart Failure Survival Score CHARM Risk Score (207) CORONA Risk Score (208) Specific to chronic HFpEF I-PRESERVE Score (202) Acutely Decompensated HF ADHERE Classification and Regression Tree (CART) Model American Heart Association Get With the Guidelines Score (200) / shtml (201) (206) / eshfstroke/getwiththeguidelinesheartfailurehomepage/get-with-the- Guidelines-Heart-Failure-Home- %20Page_UCM_306087_SubHomePage.jsp EFFECT Risk Score (203) / ESCAPE Risk Model and Discharge Score (215) OPTIMIZE HF Risk-Prediction Nomogram (216)
17 Recommendations for Biomarkers in HF Biomarker, Application Setting COR LOE Natriuretic peptides Diagnosis or exclusion of HF Prognosis of HF Ambulatory, Acute Ambulatory, Acute Achieve GDMT Ambulatory IIa B Guidance of acutely decompensated HF therapy Acute IIb C Biomarkers of myocardial injury Additive risk stratification Acute, Ambulatory I A Biomarkers of myocardial fibrosis Additive risk stratification Ambulatory Acute I I IIb IIb A A B A
18 Biomarkers in Heart Failure BNP (NT-proBNP) in Heart Failure Myocardial stress/strain/stretch BNP Ventricles > atria BNP elevated in HF Levels correlate with PCW and prognosis 18
19 Causes for Elevated Natriuretic Peptide Levels Cardiac Heart failure, including RV syndromes Acute coronary syndrome Heart muscle disease, including LVH Valvular heart disease Pericardial disease Atrial fibrillation Myocarditis Cardiac surgery Cardioversion Noncardiac Advancing age Anemia Renal failure Pulmonary causes: obstructive sleep apnea, severe pneumonia, pulmonary hypertension Critical illness Bacterial sepsis Severe burns Toxic-metabolic insults, including cancer chemotherapy and envenomation
20 2013 ACCF/AHA Guideline for the Management of Heart Failure
21 HF Risk Factor Treatment Goals HFSA 2010 Practice Guidelines 21
22 Sodium Equivalents 22
23
24 Recommendations for Treatment of Stage B Heart Failure Yancy et al JACC
25 Recommendations for Treatment of Stage B Heart Failure 25
26 Recommendations for Treatment of Stage B Heart Failure Improved M&M Start with ACEi ARB when ACEi contraindicated Routine combination ACEi/ARB contraindicated (class III) Improved Mortality (CAPRICORN) No class effect Preferred agents: Carvedilol, Metoprolol succinate, Bisoprolol Yancy et al JACC
27 Treatment of Post-MI Patients with Asymptomatic LV Dysfunction 27
28 ACE Inhibitors in HF: From Asymptomatic LVD to Severe HF 28
29 The Additional Value of Beta Blockers Post-MI: CAPRICORN 29
30
31 Pharmacological Therapy for Management of Stage C HFrEF Recommendations COR LOE Diuretics Diuretics are recommended in patients with HFrEF with fluid retention I C ACE Inhibitors ACE inhibitors are recommended for all patients with HFrEF I A ARBs ARBs are recommended in patients with HFrEF who are ACE inhibitor intolerant ARBs are reasonable as alternatives to ACE inhibitor as first line therapy in HFrEF The addition of an ARB may be considered in persistently symptomatic patients with HFrEF on GDMT ***Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful *** I IIa IIb III: Harm A A A C
32 Pharmacological Therapy for Management of Stage C HFrEF (cont.) Recommendations COR LOE Beta Blockers Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients I A Aldosterone Antagonists Aldosterone receptor antagonists are recommended in patients with NYHA class II-IV HF who have LVEF 35% I A Aldosterone receptor antagonists are recommended in patients following an acute MI who have LVEF 40% with I B symptoms of HF or DM ***Inappropriate use of aldosterone receptor antagonists may be harmful *** III: Harm B Hydralazine and Isosorbide Dinitrate The combination of hydralazine and isosorbide dinitrate is recommended for African-Americans, with NYHA class III IV HFrEF on GDMT A combination of hydralazine and isosorbide dinitrate can be useful in patients with HFrEF who cannot be given ACE inhibitors or ARBs I IIa A B
33 Pharmacologic Therapy for Management of Stage C HFrEF (cont.) Recommendations COR LOE Digoxin Digoxin can be beneficial in patients with HFrEF IIa B Anticoagulation Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke should receive chronic I A anticoagulant therapy* The selection of an anticoagulant agent should be individualized I C Chronic anticoagulation is reasonable for patients with chronic HF who have permanent/persistent/paroxysmal AF but without an additional risk factor for IIa B cardioembolic stroke* ***Anticoagulation is not recommended in patients with chronic HFrEF without AF, prior thromboembolic event, or a cardioembolic source*** III: No Benefit B Statins ***Statins are not beneficial as adjunctive therapy when prescribed solely for HF*** III: No Benefit A Omega-3 Fatty Acids Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in HFrEF or HFpEF patients IIa B
34 Pharmacological Therapy for Management of Stage C HFrEF (cont.) Recommendations COR LOE Other Drugs Nutritional supplements as treatment for HF are not recommended III: No in HFrEF Benefit B Hormonal therapies other than to replete deficiencies are not III: No recommended in HFrEF Benefit C Drugs known to adversely affect the clinical status of patients with HFrEF are potentially harmful and should be avoided or withdrawn III: Harm B Long-term use of an infusion of a positive inotropic drug is not recommended and may be harmful except as palliation Calcium Channel Blockers Calcium channel blocking drugs are not recommended as routine in HFrEF III: Harm III: No Benefit C A
35 Pharmacologic Treatment of Stage C HFrEF (Heart Failure with Reduced Ejection Fraction) 35
36 Pharmacologic Treatment of Stage C HFrEF (Heart Failure with Reduced Ejection Fraction) 36
37 ACE Inhibitors in Heart Failure: From Asymptomatic LVD to Severe HF 37
38 Effect of Beta Blockade on Outcome in Patients with HF and Post-MI LVD 38
39 COPERNICUS: EF<25%, FC III-IV (Baseline: ACEi/ARB=97%, MRA=2%, diuretics=99%, digoxin=66%) 39
40 ARBS in Patients Not Taking ACE Inhibitors: Val-HeFT & CHARM- Alternative 40
41 Aldosterone Antagonists in HF 41
42 Aldosterone Antagonists and Renal Function HFSA 2010 Practice Guidelines 42
43 Spironolactone Prescriptions After RALES Hospital Deaths After RALES 43
44 44
45 45
46 Medical Therapy for Stage C HFrEF: Magnitude of Benefit Demonstrated in RCTs 46
47 47
48 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure COR LOE Recommendation I B-R ACEI or ARB or ARNI in conjunction with β blockers + MRA (where appropriate) is recommended for patients with chronic HFrEF to reduce morbidity and mortality I B-R In patients with chronic, symptomatic HFrEF NYHA class II or III who tolerate an ACEI or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality III B-R ARNI should NOT be administered concomitantly with ACEI or within 36 hours of last ACEI dose III COR C-EO ARNI should NOT be administered to patients with a history of angioedema LOE Recommendations IIa B-R Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II-III), stable, chronic HFrEF (LVEF 35%) who are receiving GDMT, including a β blocker at maximally tolerated dose, and who are in sinus rhythm with a heart rate 70 bpm at rest 1. Yancy CW et al. J Am Coll Cardiol. 2016;68:
49 Pathophysiology of HFrEF & Therapeutic Targets adapted from Langenickel TH, Dole WP Drug Discovery Today 201;9:
50 Effects of Neprilysin Inhibition in Heart Failure 50
51 PARADIGM-HF: Primary Endpoint of CV Death or Heart Failure Hospitalization 51
52 Sac/Val vs Enalapril on Primary Endpoint and on CV Death by Subgroups 52
53 PARADIGM-HF: Effect of Sac/Val vs Enalapril on the Primary Endpoint and Its Components 53
54 PARADIGM-HF: Adverse Events 54
55 ARNI harm 2016 Focused Update 55
56 Potential Mortality Reduction with Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure 56
57 New FDA-Approved Sacubitril/Valsartan 57
58 Ivabradine 2016 Focused Update 58
59 Ivabradine 59
60 SHIFT Study: Primary Endpoint of CV Death or Hospitalization for Worsening Heart Failure 60
61 SHIFT Study: Effect of Ivabradine on Outcomes 61
62 New FDA-Approved Ivabradine 62
63 Practical Points on Use of Ivabradine 63
64 Characteristics and Outcomes of Adult Outpatients with HF and Improved or Recovered Ejection Fraction 64
65 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest Physicians, and International Society for Heart and Lung Transplantation
66
67 HFrEF: cardiomyocyte insult neurohormonal/cardiaremodeling oxidative stress/inflammation HFpEF: Diverse pathophysiological pathways & comorbidities systemic inflammatory state Cardiac remodeling
68 Butler et al, Circ Heart Fail 2016
69 HFpEF Incidence & Prevalence HFpEF Increases More Rapidly with F>M Prevalence at Any Age Registries Dhingra Curr Heart Fail Rep 2014 (EPICA study. Eur. J. Heart Fail. 2002) Studies HFpEF Cohorts Bimodal Distribution of EF in HF Dunlay S. M. et al. Circ. Heart Fail Redfield MM et al. Nature Rev 2017
70 All Heart Failure Admissions 30-50% are with Preserved Ejection Fraction
71 Risk of Subsequent Death or HF Hospitalization is Greatest When the Time from the Last Hospitalization is Shortest
72 HFpEF Mortality How Do HFpEF Patient s Die? Sudden Cardiac Death Redfield MM, et al. Nautre Rev 2017
73 Guideline Definition of Heart Failure with Preserved Ejection Fraction? 2016 ESC HF Guidelines 2013 ACC HF Guidelines In Summary: Consensus is for using EF > 50%
74 Pathophysiology of HFpEF Traditional Pathophysiological Model HFpEF is a Disease of HFpEF Not a Collection of Co-Morbidities Emerging Pathophysiological Models of HFpEF Redfield MM 2016 (Franssen, et al. 2016; Paulus & Tschope 2013) Redfield MM 2016 (Franssen, et al. 2016; Paulus & Tschope 2013)
75 Diastolic Dysfunction Most Important Mechanism in HFpef Impaired Relaxation Normal CV Ageing Diastolic Dysfunction in HFpEF Invasive Evaluation: 47 HFpEF, 10 controls Henein et al. EHJ. 2002; 23: Diastolic Dysfunction in HFpEF Echo Evaluation: 244 HFpEF, 719 HTN, 617 controls Lam Circ 2007
76 Excitation Contraction Coupling Some Proposed Mechanisms of Diastolic Dysfunction in HFpEF Nitric Oxide/Natriuretic Peptide cgmp Pathway in HF Abnormalities in Spring-like Titin Protein Dysfunctional Ca Handling Increased Extracellular Fibrosis Reduced LV compliance shift PV relationship Van Heerebeek L, et a. Paulus WJ. AHA 2011 AOS , Bers & Borlaug Braunwald s Heart Dis, 11 th Ed.
77 Comorbidity Drive Microvascular & Coronary Endothelial Oxidative Stress & Inflammation LV, RV, LA, RA Skeletal Muscle Paulus W, JACC 2013; Stasch JP, JCI 2006 Redfield MM, Mayo CV Board Rev 2016 Kato, HAHA 2016; Mohammed, Circ HF 2016 Borlaug et al, JACC 2010
78 LV Systolic Function in HFpEF Myocardial Strain In Normals, HTN, HFpEF and HFrEF Subtle Systolic Dysfunction in HFpEF Kraigher-Krainer E, JACC 2013 Knappe D, Circ HF 2011 TOPCAT, A. Shah circ 2015 Borlqug JACC 2009 Decreased Systolic Reserve in HFpEF
79 Less Physical Activity and Higher BMI Associated with HFpEF Development
80 HFpEF is Caused by Complex Interplay of Multiple Impairments Ventricular diastolic and systolic reserve Heart rate reserve and rhythm Atrial dysfunction Stiffening of the ventricles and vasculature Impaired vasodilatation Pulmonary HTN Endothelial dysfunction Abnormalities in periphery, including skeletal muscle
81 HFpEF Treatment Guidelines European Society of Cardiology HF Guidelines 2012 No treatment has yet been shown, convincingly, to reduce morbidity and mortality in patients with HF 2016 No treatment has yet been shown, convincingly, to reduce morbidity and mortality in patients with HF-PEF
82 Landmark Heart Failure RCTs NO Evidence Based Therapy Effective for HFpEF
83 Outcomes Trials in HFpEF Solomon S ESC 2017
84 HFpEF Trials cgmp-pkg, sgc, NO Pathways Solomon S, ESC 2017
85 Some Benefit in HFpEF?
86 Effect of Exercise on Training on Measures of Diastolic Function Edelmann, Pieske B JACC 2011
87 2017 ACC Focused Update HF Guidelines Treatment of HFpEF
88 HFpEF Putting It All Together Assess alternative comorbidities ICH, Circ Heart Fail 2016 Redfield MM, Mayo CV Board Rev 2016 Redfield MM et al, Nature Rev 2017 Additional Objective Options: Diastolic Stress testing CPET Right & left cardiac cath EDP, CO
89 Thank you!!!
90 Top Ten Things to Know 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure 1. Heart Failure (HF) prevalence has increased from 5.7 million to 6.5 million in Americans 20 years of age and projections show prevalence will increase by 46% from 2012 to 2030 resulting in more than 8 million people 18 years of age and older with HF. 2. This update represents the second of a two-stage publication with the 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure which incorporated the use of an angiotensin receptor neprilysin inhibitor (ARNI) (valsartan/sacubitril) and a sinoatrial node modulator (ivabradine) for patients with heart failure with reduced ejection fraction (HFrEF). 90
91 Top Ten Things to Know 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure 3. This focused update includes the recommendations for these newer pharmacotherapies, revisions to the sections on biomarkers, heart failure with preserved ejection fraction (HFpEF), important comorbidities including sleep apnea, anemia and hypertension, and insights regarding HF prevention. 4. For patients at risk of developing heart failure, use of natriuretic peptide biomarker-based screening followed by team-based care including a cardiovascular specialist optimizing guideline-directed management and therapy (GDMT) can be useful to prevent the development of Left Ventricular (LV) dysfunction (systolic or diastolic) or new onset HF. 5. Based on observational studies, for patients hospitalized with HF, a predischarge natriuretic peptide level can be useful to establish a post-discharge prognosis. 91
92 Top Ten Things to Know 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure 6. For the pharmacologic treatment of Stage C HFpEF, aldosterone receptor antagonists might be considered in appropriately selected patients; however, routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or quality of life (QoL) in patients is not effective. 7. For patients with New York Heart Association (NYHA) class II and III HF with comorbid iron deficiency anemia, intravenous iron replacement might be reasonable to improve functional status and QoL; however, use of erythropoietin stimulating agents in patients with HF and anemia should not be used. 8. Recommendations and goals for blood pressure management have been added for patients at risk of developing HF (Stage A HF) and those with both Stage C HFrEF with hypertension and HFpEF with persistent hypertension. 92
93 Top Ten Things to Know 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure 9. A formal sleep assessment is reasonable for patients with NYHA class II-IV HF and suspicion of sleep disordered breathing or excessive daytime sleepiness. - Importance of diagnosing obstructive versus central sleep apnea. - Treating patients with NYHA class II-IV HFrEF and central sleep apnea with adaptive servo-ventilation (ASV) causes harm and is not recommended. 10. This focused update incorporates new data since the previous publication and emphasizes important topics including - HF prevention, - - hypertension management, and - treatment of common comorbid conditions. 93
The ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationHeart.org/HFGuidelinesToolkit
2017 /H/HFS Focused Update of the 2013 F/H 6.3.1 Biomarkers for Prevention: Recommendation OR LOE Recommendation a For patients at risk of developing HF, natriuretic peptide biomarker-based screening followed
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationCitation. What is New in the 2013 ACC/AHA HF Guideline. Dimensions in Heart and Vascular Care Penn State Heart and Vascular Institute
What is New in the 2013 ACC/AHA HF Guideline Dimensions in Heart and Vascular Care Penn State Heart and Vascular nstitute Friday October 18, 2013 Barry S. Clemson, MD Associate Professor of Medicine Penn
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationUpdate in Congestive Hear Failure DRAGOS VESBIANU MD
Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationRole of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association We combed through both guidelines and summarized 3 recommendations
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationFINANCIAL DISCLOSURE: No relevant financial relationship exists
The Value of Guideline Directed Medical Therapy in Heart Failure Steve Dentel RN BSN CPHQ National Director, Field Programs and Integration American Heart Association/American Stroke Association FINANCIAL
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More information578 Index. Eplerenone, 7, 29, 119, 120, 126, 275, 276,
Index A AC. See Adenylate cyclase (AC) ACEI. See Angiotensin converting enzyme inhibitors (ACEI) Adenosine, 179, 180, 182 184, 191, 196 198 Adenosine A1 receptor, 179 183, 186, 190 198 Adenylate cyclase
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationManagement of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA
Management of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA Declaration of potential conflict of interests Type of job or financial support Salary Ordinary funds Position in
More informationSaudi Heart Failure Guidelines. Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group
Saudi Heart Failure Guidelines Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group Heart Failure Expert committee The Heart Failure Expert Committee,
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationThe Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationThe NEW Heart Failure Guidelines
The NEW Heart Failure Guidelines Daily Practice HF scenario of the Case Presentations HF as a complex and heterogeneous syndrome Several proposed pathophysiological mechanisms involving the heart and the
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
ACC/AHA/HFSA FOCUSED UPDATE 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationOHSU HEALTH SYSTEM OFFICE OF CLINICAL INTEGRATION AND EVIDENCE-BASED PRACTICE
OHSU HEALTH SYSTEM OFFICE OF CLINICAL INTEGRATION AND EVIDENCE-BASED PRACTICE GUIDELINE FOR THE MANAGEMENT OF HEART FAILURE Background: Heart failure (HF) is a complex clinical syndrome that results from
More informationChronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationDiagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham
Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Chronic heart failure
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationUPDATE HEART FAILURE MANAGEMENT
Save Thais from Heart Diseases 2019 UPDATE HEART FAILURE MANAGEMENT Orawan Anupraiwan, MD. Central Chest Institute of Thailand Definition of HF Heart failure is a clinical syndrome characterized by typical
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationEjection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction
Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 4 2 3.5 4. 1. 1991 21 237 US prevalence*: 5. million US annual incidence: 7, Annual mortality: 22,754 5-1% depending on severity Cost:
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationNew CHF Patient in my Office: What Should I Do?
New CHF Patient in my Office: What Should I Do? Joseph Mishkin MD FACC Advanced Heart Failure, Transplantation and Mechanical Circulatory Support No disclosures Disclosures Clinical Presentation 38 year
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationDiagnosing Heart Failure in Primary Care: Differentiating Zebras from Horses
Diagnosing Heart Failure in Primary Care: Differentiating Zebras from Horses CANP March 2015 Maria Fe White, ACNP-BC Advanced Heart Disease Clinic Comprehensive Transplant Center Cedars-Sinai Medical Center
More information9/10/ , American Heart Association 2
Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP Vice Dean, Diversity & Inclusion Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Division of Cardiology Northwestern University, Feinberg
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationManagement of Heart Failure in Older Adults
Management of Heart Failure in Older Adults New Data, New Guidelines, New Challenges JOSE NATIVI, MD, MSCI Assistant Professor of Medicine Cardiovascular Director Amyloidosis Program DISCLOSURES - Advisory
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More informationHeart Failure in Women
Heart Failure in Women Disclosure Professor Sindone has received honoraria, speaker fees, consultancy fees, is a member of advisory boards or has appeared on expert panels for: Professor Andrew Sindone
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More information